Yasuhiro Matsubayashi

Yasuhiro Matsubayashi

Auto-generated profile, based on publicly available information

Yasuhiro Matsubayashi

Department of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine Niigata Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2021 in JMIR Diabetes
Verified
Journal Article
Open access
SKSatoru Kodama
Satoru Kodama
KFKazuya Fujihara
Kazuya Fujihara
HSHaruka Shiozaki
Haruka Shiozaki
Chika HorikawaChika Horikawa
Chika Horikawa
MYMayuko Harada Yamada
Mayuko Harada Yamada
HSHirohito Sone
Hirohito Sone
Background: Machine learning (ML) algorithms have been widely introduced to diabetes research including those for the identification of hypoglycemia. Objective: The objective of this meta-analysis is to assess the current ability of ML algorithms to detect hypoglycemia (ie, alert to hypoglycemia coinciding with its symptoms) or predict hypoglycemia (ie, alert to hypoglycemia before its symptoms have occurred). Methods: Electronic literature searches (from January 1, 1950, to September 14, 2020) were conducted using the Dialog platform that covers 96 databases of peer-reviewed literature. Included studies had to train the ML algorithm in order to build a model to detect or predict hypoglycemia and test its performance. The set of 2 × 2 data (ie, number of true positives, false positives, true negatives, and false negatives) was pooled with a hierarchical summary receiver operating characteristic model. Results: A total of 33 studies (14 studies for detecting hypoglycemia and 19 studies for predicting hypoglycemia) were eligible. For detection of hypoglycemia, pooled estimates (95% CI) of sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were 0.79 (0.75-0.83), 0.80 (0.64-0.91), 8.05 (4.79-13.51), and 0.18 (0.12-0.27), respectively. For prediction of hypoglycemia, pooled estimates (95% CI) were 0.80 (0.72-0.86) for sensitivity, 0.92 (0.87-0.96) for specificity, 10.42 (5.82-18.65) for PLR, and 0.22 (0.15-0.31) for NLR. Conclusions: Current ML algorithms have insufficient ability to detect ongoing hypoglycemia and considerate ability to predict impeding hypoglycemia in patients with diabetes mellitus using hypoglycemic drugs with regard to diagnostic tests in accordance with the Users’ Guide to Medical Literature (PLR should be ≥5 and NLR should be ≤0.2 for moderate reliability). However, it should be emphasized that the clinical applicability of these ML algorithms should be evaluated according to patients’ risk profiles such as for hypoglycemia and its associated complications (eg, arrhythmia, neuroglycopenia) as well as the average ability of the ML algorithms. Continued research is required to develop more accurate ML algorithms than those that currently exist and to enhance the feasibility of applying ML in clinical settings. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42020163682; http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42020163682

27 February 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AYAkihiro Yoshida
Akihiro Yoshida
YMYasuhiro Matsubayashi
Yasuhiro Matsubayashi
TNToshiaki Nojima
Toshiaki Nojima
HSHideki Suganami
Hideki Suganami
TATakahiro Abe
Takahiro Abe
HSHirohito Sone
Hirohito Sone
Context Although calorie loss from increased urinary glucose excretion continues after long-term treatment with SGLT2 inhibitors, the mechanisms of the attenuated weight loss due to SGLT2 inhibitors are not well known. Objective To examine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2 inhibitor, tofogliflozin, focussing on the antilipolytic effect of insulin on adipose tissue. Design and Participants An integrated analysis was performed using data from two Phase 3 studies of 52 weeks of tofogliflozin administration. The antilipolytic effect was evaluated using adipose tissue insulin resistance (Adipo-IR) calculated from the product of fasting insulin (f-IRI) and fasting free fatty acids (f-FFA). Results Analysed were 774 patients with type 2 diabetes (mean age 58.5 years; HbA1c 8.1%; BMI 25.6 kg/m2; eGFR 83.9 mL/min/1.73m2; 66% men). Weight loss plateaued between Weeks 24 and 52 after decreasing significantly. f-IRI decreased significantly from baseline to Week 24, and the decrease was maintained until Week 52. f-FFA significantly increased, peaked at Week 24, then declined from Weeks 24 to 52. Adipo-IR declined progressively throughout the 52 weeks (-3.6 and -6.2 mmol/L·pmol/L at Weeks 24 and 52, respectively, (p<0.001) vs. baseline). Higher baseline Adipo-IR levels were independently associated with greater weight loss at Week 52. Conclusions The improved antilipolytic effect in adipose tissue may attenuate progressive lipolysis leading to attenuating future weight loss induced by an SGLT2 inhibitor in patients with type 2 diabetes.

27 January 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
YMYasuhiro Matsubayashi
Yasuhiro Matsubayashi
AYAkihiro Yoshida
Akihiro Yoshida
HSHideki Suganami
Hideki Suganami
TOTaeko Osawa
Taeko Osawa
KFKazuo Furukawa
Kazuo Furukawa
HSHirohito Sone
Hirohito Sone
Aims: Obesity and hepatic fat accumulation diminish hepatic insulin clearance, which can cause hyperinsulinaemia. Sodium/glucose‐cotransporter 2 inhibitors (SGLT2‐is) improve insulin resistance and hyperinsulinaemia by weight loss via increased urinary glucose excretion in type 2 diabetes. However, there are few reports of the influence of SGLT2‐is on hepatic insulin clearance. We examined the impact of an SGLT2‐i on hepatic insulin clearance and explored the clinical influence associated with changes in hepatic insulin clearance via an SGLT2‐i and the mechanism of the effects of SGLT2‐i. Materials and methods: Data were analysed from 419 patients with type 2 diabetes controlled by diet and exercise. Patients received a placebo or the SGLT2‐i tofogliflozin (TOFO) (placebo: n = 56; TOFO: n = 363) orally once daily for ≥24 weeks. Hepatic insulin clearance was calculated from the ratio of areas under the curve (AUC) of C‐peptide and insulin levels derived from oral meal tolerance test data (C‐peptide AUC 0‐120 min /insulin AUC 0‐120 min : HIC CIR ). The correlation of HIC CIR via the SGLT2‐i with other clinical variables was analysed using multivariate analysis. Results: HIC CIR was significantly increased via TOFO at week 24. Furthermore, with TOFO insulin and triglyceride (TG) levels were significantly reduced ( P < 0.001) and β‐hydroxybutyrate (BHB) was significantly elevated ( P < 0.001). Changes in HIC CIR were significantly correlated with changes in TG and BHB via TOFO. Conclusions: Increased HIC CIR was significantly associated with reduced TG via TOFO and contributed to the greater increase in BHB compared with placebo in addition to the correction of hyperinsulinaemia.

1 January 2021 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
PDF file
MKMasanori Kaneko
Masanori Kaneko
KFKazuya Fujihara
Kazuya Fujihara
MHMayuko Yamada Harada
Mayuko Yamada Harada
TOTaeko Osawa
Taeko Osawa
MYMasahiko Yamamoto
Masahiko Yamamoto
HSHirohito Sone
Hirohito Sone
Background: The prevalence of diabetes is rising, and diabetes develops at a younger age in East Asia. Although lower limb amputation negatively affects quality of life and increases the risk of cardiovascular events, little is known about the rates and predictors of amputation among persons with diabetes from young adults to those in the “young‐old” category (50–72 y).Methods: We analyzed data from a nationwide claims database in Japan accumulated from 2008 to 2016 involving 17,288 people with diabetes aged 18–72 y (mean age 50.2 y, HbA1c 7.2%). Amputation occurrence was determined according to information from the claims database. Cox regression model identified variables related to lower limb amputation.Results: The mean follow‐up time was 5.3 years, during which time 16 amputations occurred (0.17/1000 person‐years). Multivariate Cox regression analysis showed that age (hazard ratio [HR] 1.09 [95% confidence intervals] 1.02–1.16, p = 0.01) and HbA1c (HR 1.46 [1.17–1.81], p < 0.01) were independently associated with amputations. Compared with those aged < 60 years with HbA1c < 8.0%, the HR for amputation was 27.81 (6.54–118.23) in those aged ≥60 years and HbA1c ≥8.0%.Conclusions: Age and HbA1c were associated with amputations among diabetic individuals, and the rates of amputation were significantly greater in those ≥60 years old and with HbA1c ≥8.0%.

16 May 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
MNMegumi Nokihara
Megumi Nokihara
KFKazuya Fujihara
Kazuya Fujihara
YYYuta Yaguchi
Yuta Yaguchi
HTHiroki Takizawa
Hiroki Takizawa
LKLaymon Khin
Laymon Khin
HSHirohito Sone
Hirohito Sone

27 January 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
KFKazuya Fujihara
Kazuya Fujihara
YMYasuhiro Matsubayashi
Yasuhiro Matsubayashi
MYMayuko Harada Yamada
Mayuko Harada Yamada
MYMasahiko Yamamoto
Masahiko Yamamoto
TIToshihiro Iizuka
Toshihiro Iizuka
HSHirohito Sone
Hirohito Sone
Background: Applications of machine learning for the early detection of diseases for which a clear-cut diagnostic gold standard exists have been evaluated. However, little is known about the usefulness of machine learning approaches in the decision-making process for decisions such as insulin initiation by diabetes specialists for which no absolute standards exist in clinical settings. Objective: The objectives of this study were to examine the ability of machine learning models to predict insulin initiation by specialists and whether the machine learning approach could support decision making by general physicians for insulin initiation in patients with type 2 diabetes. Methods: Data from patients prescribed hypoglycemic agents from December 2009 to March 2015 were extracted from diabetes specialists’ registries, resulting in a sample size of 4860 patients who had received initial monotherapy with either insulin (n=293) or noninsulin (n=4567). Neural network output was insulin initiation ranging from 0 to 1 with a cutoff of >0.5 for the dichotomous classification. Accuracy, recall, and area under the receiver operating characteristic curve (AUC) were calculated to compare the ability of machine learning models to make decisions regarding insulin initiation to the decision-making ability of logistic regression and general physicians. By comparing the decision-making ability of machine learning and logistic regression to that of general physicians, 7 cases were chosen based on patient information as the gold standard based on the agreement of 8 of the 9 specialists. Results: The AUCs, accuracy, and recall of logistic regression were higher than those of machine learning (AUCs of 0.89-0.90 for logistic regression versus 0.67-0.74 for machine learning). When the examination was limited to cases receiving insulin, discrimination by machine learning was similar to that of logistic regression analysis (recall of 0.05-0.68 for logistic regression versus 0.11-0.52 for machine learning). Accuracies of logistic regression, a machine learning model (downsampling ratio of 1:8), and general physicians were 0.80, 0.70, and 0.66, respectively, for 43 randomly selected cases. For the 7 gold standard cases, the accuracies of logistic regression and the machine learning model were 1.00 and 0.86, respectively, with a downsampling ratio of 1:8, which were higher than the accuracy of general physicians (ie, 0.43). Conclusions: Although we found no superior performance of machine learning over logistic regression, machine learning had higher accuracy in prediction of insulin initiation than general physicians, defined by diabetes specialists’ choice of the gold standard. Further study is needed before the use of machine learning–based decision support systems for insulin initiation can be incorporated into clinical practice.